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Objectives: Age is the most prominent predisposition for development of osteoarthritis (OA). Age-related
changes of articular cartilage are likely to play a role. Advanced glycation endproducts (AGEs) accumulate
in cartilage matrix with increasing age and adversely affect the biomechanical properties of the cartilage
matrix and inﬂuence chondrocyte activity. In clinical studies AGEing of cartilage and its relation to actual
cartilage damage can only be measured by surrogate markers (e.g., serum, skin or urine AGE levels and
imaging or biochemical markers of cartilage damage). In this study actual cartilage AGE levels were
directly related to actual cartilage damage by use of cartilage obtained at joint replacement surgery.
Methods: Cartilage and urine samples were obtained from 69 patients undergoing total knee replace-
ment. Samples were analyzed for pentosidine as marker of AGE. Cartilage damage was evaluated
macroscopically, histologically, and biochemically.
Results: Cartilage and urine pentosidine both increased with increasing age. The higher the macroscopic,
histological, and biochemical cartilage damage the lower the cartilage pentosidine levels were. In
multiple regression analysis age is not found to be a confounder.
Conclusion: There is an inverse relation between cartilage AGEs and actual cartilage damage in end-stage
OA. This is likely due to ongoing (ineffective) increased turnover of cartilage matrix proteins even in end
stage disease.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a slowly progressive degenerative joint
disease characterized by gradual loss of articular cartilage, of which
the aetiology is multifactorial. The incidence of OA increases
strongly with age: >50% of the population over 60 years of age
shows signs of cartilage damage1.
Although age is identiﬁed as the main risk factor for the
development of OA, the mechanism by which ageing is involved,
remains largely unclear. In addition to senescence of chon-
drocytes2, age-related changes in the articular cartilage matrix are
expected to play an important role in the susceptibility of cartilage.P.J.G. Lafeber, Rheumatology
entre Utrecht, PO Box 85500,
1; Fax: 31-30-2523741.
Lafeber).
s Research Society International. Pto OA. One of the major age-related changes in articular cartilage is
the accumulation of advanced glycation endproducts (AGEs). These
AGEs are formed by non-enzymatic glycation, a spontaneous
reaction of reducing sugars with proteins3. AGEs are irreversible
chemical modiﬁcations of proteins. High tissue protein turnover
results in less accumulation. As such, AGEs accumulate with age in
long-lived proteins, for example in collagens and proteoglycans
(PGs) of cartilage tissue4. As a consequence of this accumulation of
AGEs in cartilage, increased stiffness and brittleness of the tissue
occurs, making it more prone to mechanical damage5,6. In addition
to affecting the mechanical properties of the cartilage tissue, also
cellular processes are disturbed resulting in decreased reparative
capacity of the chondrocytes7,8. All together, these effects render
the tissue more prone to damage that may eventually lead to the
development of OA.
Most of the AGEs are neither yet isolated nor characterized.
Therefore, a few well-characterized AGEs are routinely used asublished by Elsevier Ltd. All rights reserved.
P.A.J.M. Vos et al. / Osteoarthritis and Cartilage 20 (2012) 233e240234marker for the process of non-enzymatic glycation. Pentosidine,
a ﬂuorescent AGE, formed by a crosslink between lysine and argi-
nine residues, is often used for this purpose9. In post-mortem
studies, the cartilage pentosidine amount increases with age8.
Furthermore, in normal cartilage of joints with macroscopic OA the
level of pentosidine is increased compared to cartilage of joints
without signs of OA10. This suggests involvement of AGEs in the
onset of cartilage damage.
In humans, most studies on cartilage AGEs and OA are ex-vivo
studies or studies using surrogate markers of cartilage AGEing.
Pentosidine of skin biopsies, as a surrogate marker of cartilage
pentosidine, weakly correlates with radiographic OA in hips and
knees in a cohort with very early OA11. Skin ﬂuorescence, as
a marker of skin AGEing and with that cartilage AGEing, showed no
difference between severe OA versus no OA12. Also AGE levels of
more easily accessible tissues such as serum and urine are used as
surrogates. Serum pentosidine concentrations were signiﬁcantly
higher in OA patients compared to healthy controls, however no
relation with severity of radiographic OA was found13. Others
demonstrated that serum pentosidine levels can predict radio-
graphic joint space narrowing after 2 years in knee OA patients
fulﬁlling the ACR criteria and <3 years of symptoms14. Urinary
pentosidine levels were higher in participants with OA eligible for
joint replacement surgery compared to healthy controls15.
However, urinary pentosidine does not seem to predict cartilage
loss on magnetic resonance imaging (MRI)16. In a large cohort of
early OA no relationship between urinary pentosidine and radio-
graphic OA was found although a relation with urinary CTXII as
a marker of cartilage damage was evident11.
Cleary, relations between AGEing and cartilage damage are
found although results are far from conclusive. This may be due to
the limited relation between cartilage AGE levels and AGE levels of
surrogate compartments such as skin, serum, and urine (e.g., ref.
11,17). Also surrogate markers of cartilage damage (radiography and
MRI) and actual cartilage damage are limited (e.g., ref. 18e20).
Thus far, a direct relation between cartilage pentosidine levels
and cartilage tissue damage, has not been made. Therefore, the
present study compares cartilage AGE levels (as well as urinary AGE
levels) in OA directly with actual cartilage damage by use of
macroscopic, histological, and biochemical analyses.Materials and methods
Patients
Sixty-nine patients with severe knee OA, who were eligible for
total knee replacement surgery, were included between December
2007 and June 2009. Exclusion criteria were total knee replacement
for other reasons than OA and kidney disorders. This study was
conducted according to the declaration of Helsinki and received
ethics approval. Each patient gave written informed consent before
participating in the study. Knee radiographs of all patients were
available.Sample collection
At joint replacement surgery, remaining cartilage was obtained
from femoral condyles. This tissue was kept in phosphate buffered
saline for less than 4 h and subsequently processed under laminar
ﬂow conditions. The cartilage surface was macroscopically graded:
0 ¼ ﬁbrillation or focal degeneration, 1 ¼ degeneration at multiple
locations, 2 ¼ degeneration at multiple locations with focal lesions,
and 3 ¼ degeneration throughout the tissue with severe focal
lesions and focally full cartilage abrasion.Cartilage was cut aseptically from the underlying bone (full
thickness), and cut into small pieces weighing between 5 and 15mg
(accuracy 0.1 mg). Two randomly selected samples were used to
determine cartilage pentosidine. Four randomly selected samples
of each donor were ﬁxed in 4% phosphate buffered formalin in 2%
sucrose and stained with Safranin-O fast greeneiron haematoxylin
for histochemistry. These samples were graded for microscopic
features of OA, using the modiﬁed Mankin criteria21. Two observers
blinded to the source of the cartilage graded the cartilage and the
averages of the two observers and the four samples were taken as
representative score of each donor. Twenty samples were randomly
selected for biochemistry including PG synthesis, -retention,
-release, and -content.
To obtain a surrogate marker of cartilage pentosidine as well,
urine samples of each patient was collected shortly before the
operation and stored at 80C immediately for pentosidine
analyses.
AGE measurement in cartilage and urine
Pentosidine was used as a representative measure of AGEs,
representing other AGE measures as well17. Pentosidine levels in
cartilage were measured as described previously17. Articular carti-
lage collagen was isolated by depleting the tissue of all PGs and
other non-collagenous proteins using sequential enzymatic treat-
ment with chondroitinase ABC (Sigma), trypsin (Roche Molecular
Biochemicals), and Streptomyces hyaluronidase (Sigma) for 20 h at
37C4. Next, collagen samples were digested for 2 h at 65C with
5 units/ml papain (from Papaya latex, Sigma) in 300 ul of papain
buffer [50 mM phosphate buffer (pH 6.5), 2 mM L-cysteine, and
2 mM EDTA]. An aliquot of the papain digests was subsequently
hydrolyzed in 1 ml of 6 M HCl at 100C for 18 h. Hydrolyzed
cartilage collagen was dried (Speed Vac; Savant, Holbrook, NY),
washed (1 ml milliQ water), dried again, and dissolved in water
containing the internal standards pyridoxine (10 mM; Sigma) and
homoarginine (2.4 mM; Sigma). Samples were diluted four-fold
with 1% heptaﬂuorbutyric acid in 10% acetonitrile and analyzed for
pentosidine content by high-performance liquid chromatography
(HPLC)22. The column (Varian, Sunnyvale, CA, USA) was equili-
brated with 0.15% (v/v) HFBA in 24% (v/v) methanol (solvent A).
Elution of the crosslinks and the internal standard pyridoxine was
achieved at ambient temperature at a ﬂow-rate of 1.0 ml/min in
two isocratic steps: time 0e17 min solvent A; time 17e30 min
0.05% (v/v) HFBA in 40% (v/v) methanol (solvent B). The column
was washed with 0.1% (v/v) HFBA in 75% (v/v) acetonitrile (solvent
C) for 10 min and equilibrated for 10 min with solvent A, resulting
in a total analysis time of 50 min per sample. For amino acid
analysis, an aliquot of the pentosidine samples was diluted 200-fold
with 0.1 M borate buffer (pH 11.4) and derivatized with
9-ﬂuorenylmethyl chloroformate (6 mM in acetone). After termi-
nation of the derivatization reaction and removal of excess reagent
by triplicate extraction with pentane, samples were diluted three-
fold with 25% (v/v) acetonitrile in borate buffer (pH 8) and analyzed
by HPLC23.
The pentosidine content of collagen samples is expressed as
millimoles per mole collagen, assuming 300 hydroxyproline resi-
dues per triple-helical collagen molecule23. A calibration curve
(R2 ¼ 0.999) was used (0e12.5 pmol pentosidine/ml). The %CV was
on average 6.8% for the various pentosidine concentrations within
the calibration curve.
Urine pentosidine was measured by HPLC16 in diluted non-
hydrolysed urine (1:1 in 0.025% H2SO4) following injection of 50 ml
on aWhatman partisik 10 SCX column (250 4.6 mm). Pentosidine
was eluted using an isocratic gradient of 0.025% H2SO4 and 100mM
Al2(SO4)3 in 0.025% H2SO4. Column temperature was kept at 60C
Table I
Baseline characteristics of the 69 patients included in this study
Mean  SD Count N
Age (years) 68.8  9.0 Macroscopy 1.5 6
BMI (kg/m2) 29.1  5.2 2 17
Ln cartilage pentosidine/
collagen (nmol/mol)
1.92  5.2 2.5 16
Ln urine pentosidine/
creatinine (pmol/mmol)
0.12  0.51 3 20
Histology cartilage 4.78  1.08 K&L score 2 9
PG synthesis (nmol h g) 2.33  0.96 2.5 1
PG release (%) 11.69  4.25 3 35
Newly formed GAG
released (%)
15.11  8.4 3.5 2
PG content (mg/g) 24.26  6.5 4 22
Gender (female/male) 50/19
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at 328 nm (ex) 378 nm (em). Puriﬁed pentosidine calibrated by
mass spectroscopy served as a reference. Urinary creatinine was
determined by a standard enzyme-linked immunosorbent assay
(ELISA) (Creatinine assay kit, Cayman Chemicals). Urinary pento-
sidine values were normalized by urinary creatinine to account for
urinary dilution.
Radiographic score
The knee radiographs were scored by two individuals according
to the Kellgren and Lawrence (K&L) score24 unaware of other data
from each patient. The average of both scores was used for statis-
tical analysis.
Biochemical analysis
As measure of the PG synthesis rate, sulphate incorporation rate
was determined over a 4-h period. After 1 h of pre-culture (equil-
ibration) culture medium was refreshed and Na2SO42 (DuPont
NEX-o41-H, carrier free) 370 kBq added as described before25. After
4-h labelling period, the cartilage explants were rinsed once,
washed three times for 45 min in culture medium under culture
conditions, and subsequently cultured, individually for an addi-
tional period of 3 days. After this period cartilage and culture
mediumwere separated, cartilage was rinsed in cold PBS and both,
cartilage samples and culture mediumwere snap frozen and stored
at 20C for no longer than 7 days.
For PG synthesis and -content, cartilage samples were digested
in papain buffer as described before26. Papain digests were diluted
to the appropriate concentrations and glycosaminoglycans (GAGs)
were stained, precipitated with Alcian Blue dye solution27, and
subsequently dissolved in sodium dodecyl sulphate (SDS). The
35SO42 radioactivity of the sample was measured by liquid scintil-
lation analysis. The 35SO42 incorporation was normalized to the
speciﬁc activity of the medium, labelling time and wet weight of
the cartilage samples. The PG synthesis rate is expressed as nano-
moles of sulphate incorporated per hour per gram wet weight of
the cartilage (nmol/h g). Blue staining, as a measure for the PG
content, was quantiﬁed photometrically by the change in absor-
bance at 620 nm. Chondroitin sulphate was used as reference.
Values were normalized to the wet weight of the cartilage and
expressed milligrams of GAGs per gram wet weight of cartilage
tissue (mg/g).
Part of the culture medium was used to analyze the release of
newly formed PGs and total PG release. For release of the PGs, GAGs
were precipitated from the 3-day culture medium and stained with
Alcian Blue27. The radio-labelled GAGs were measured by liquid
scintillation analysis and normalized to the PG synthesis rate and
expressed as percentage release of newly formed PGs, being
a measure of retention of newly formed PGs. For the total release of
PGs blue staining was quantiﬁed photometrically by the change in
absorbance at 620 nm (chondroitin sulphate used as reference).
Values were normalized to the GAG content of the explants and
expressed as a percentage release.
Calculations and statistical analysis
Because of focal differences in composition and bioactivity of
the knee cartilage (speciﬁcally in case of severe OA) the results of
multiple cartilage samples per parameter per patient (obtained at
random and handled individually; 2, 4, and 20 for pentosidine,
histochemistry, and biochemistry, respectively) were averaged and
taken as a representative value for the cartilage of that patient.
Cartilage and urine pentosidine were ln transformed, to obtainnormal distribution. Differences between groups were analyzed by
ManneWhitney U test, correlations were tested using Pearson or
Spearman correlation depending on normal distribution. Multiple
regression analysis was used to correct relations for potential
confounders, age, gender, and body mass index (BMI). Data were
checked graphically using a histogram and normal probability plot
of the residuals. The observed and predicted outcomes were
plotted against each other to check for heteroscedasticity. There
was a homogeneity of variance and datawere normally distributed.
P values less than or equal to 0.05 were considered statistically
signiﬁcant. SPSS software version 15.0 was used.
Results
Baseline characteristics
In Table I the baseline characteristics of the cohort are described.
The values for the different parameters are typically for OA patients
with severe knee OA who were eligible for total knee
replacement25.
Pentosidine
Cartilage pentosidine levels increased statistically signiﬁcant
with age [R¼ 0.493, P< 0.001; Fig. 1(A)]. Also the urine pentosidine
increased with age [R ¼ 0.535, P < 0.001; Fig. 1(B)]. Cartilage
pentosidine correlated with urine pentosidine; with increasing
cartilage pentosidine the urine pentosidine increased (R ¼ 0.307,
P ¼ 0.016; data not shown).
Cartilage pentosidine and damage
Cartilage integrity
No clear difference in cartilage pentosidine was found between
patients with the highest macroscopic level of cartilage damage (an
ordinal scale, macroscopic score >2.5) and those with lower
macroscopic damage (macroscopic score 2.5) although a tendency
can be anticipated relating low cartilage pentosidine levels with
high macroscopic damage [Fig. 2(A), P ¼ 0.192]. For the cartilage
histology an inverse relation was seen; patients with the highest
histological cartilage damage had the lowest cartilage pentosidine
levels [continuous scales, R ¼ 0.428, P ¼ 0.001; Fig. 2(B)].
Cartilage biochemistry and chondrocyte activity
The inverse correlation between cartilage damage and cartilage
pentosidine levels was further corroborated by the biochemical
data. Cartilage with the lowest PG content showed the lowest
cartilage pentosidine levels [Fig. 3(A); although not statistically
Fig. 1. The correlation of cartilage (A) and urine (B) pentosidine with age (N ¼ 64). For both a positive correlation was found.
Fig. 2. The relation of cartilage pentosidine with the macroscopic cartilage damage (A). The data are presented as mean (square) with two times SD (upper and lower limit). When
the macroscopic cartilage damage is dichotomized (N ¼ 58) no clear relationship between the pentosidine levels and macroscopic score was found although a tendency towards
a higher macroscopic OA with lower pentosidine amount can be anticipated. (B): Negative correlation between microscopic cartilage damage and cartilage pentosidine levels
(R ¼ 0.428, P ¼ 0.001; N ¼ 59). A higher microscopic OA score correlated with lower cartilage pentosidine levels.
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Fig. 3. The biochemical markers of the cartilage in relation to cartilage pentosidine (N ¼ 60). (A): PG content, (B): PG synthesis, (C): % total PG release, and (D): % newly formed PG
released (as a measure for retention of newly formed PGs). No correlation is found for cartilage pentosidine with the PG content. The PG synthesis increases with increasing
pentosidine, for the % total and % newly formed PGs a negative relation is found.
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pentosidine levels [R ¼ 0.443, P < 0.001; Fig. 3(B)]. The highest
release of PGs, resident as well as newly formed, was found in
cartilage with the lowest pentosidine levels [Fig. 3(C), R ¼ 0.392,
P ¼ 0.002 and Fig. 3(D), R ¼ 0.400, P ¼ 0.002, respectively].
Pentosidine and K&L score
In general, a high K&L score was found (59/69  3; lowest score
2 see Table I). No correlation between the radiographic score and
cartilage parameters (biochemical as well as histological; data not
shown) was found. The variation in K&L score was low; due to
a cohort with severe OA, and therefore a correlation with cartilage
parameters is difﬁcult to ﬁnd. No relationship between cartilage
pentosidine levels and radiographic damage was found.
Urine pentosidine and cartilage damage
No clear relations between urine pentosidine and macroscopic
andmicroscopic cartilage damage could be found (data not shown).
For the biochemical cartilage parameters, similar correlations were
found as for cartilage pentosidine levels, although less profound
(PG content: R ¼ 0.057, P ¼ 0.667; PG synthesis rate: R ¼ 0.279,
P ¼ 0.032; total PG release: R ¼ 0.288, P ¼ 0.027; newly formed
GAG release: R ¼ 0.292, P ¼ 0.025). Also, no relationship between
urine pentosidine levels and radiographic damage was found.
Multiple regression analysis
Cartilage pentosidine is strongly correlated with age. Multiple
regression analysis was used to separate the effect of age and
pentosidine on cartilage damage (Table II). Different outcome
parameters were each used as dependent variable and ln skin
pentosidine/collagen and age as independent variable entered
backwards on either statistical signiﬁcance or a decrease of 10% or
more in the regression coefﬁcient of skin pentosidine. In this
multivariate analysis, pentosidine but not age, predicts cartilagehistology, PG synthesis, % total PG and newly formed GAG released
as independent variable. This implies that cartilage damage is
related to cartilage pentosidine without age being a confounder. In
most cases the explained variance was around 40% (R2w 0.4). This
means that cartilage pentosidine explains w40% of the separate
outcome measurements.
If gender and BMI were added in these models no extra
explained effect was observed so these factors have no additional
effect in explaining cartilage damage (see Table IIb online with the
additional parameters included).Discussion
The purpose of this study was the direct evaluation of cartilage
(and urine) pentosidine levels and the relation with the actual
macroscopic, microscopic, and biochemical cartilage damage.
Based on literature where surrogate markers of cartilage damage
were used, there was a clear positive relation expected (more
cartilage damage, higher pentosidine levels). However, the present
study, using direct markers of cartilage damage, showed opposite
effects for several parameters (more cartilage damage, lower pen-
tosidine levels) in end stage disease.
As is seen in other studies the pentosidine levels increase with
age in this cohort (Fig. 1), although we found a lower correlation
coefﬁcient compared to the historical data (R ¼ 0.493 vs R ¼ 0.93,
respectively)8. In the latter case, the cartilage samples were ob-
tained from donors of a wider range of age (33e83 compared to
50e88 years in the current study), which might explain the lower
correlation coefﬁcient.
We found a lower amount of cartilage pentosidine levels in the
cartilage with histological cartilage damage contrasting previous
data. This inverse relationwas further supported by the correlations
with the biochemical data,most clearly in the total PG release and the
release of newly formed PGs. A possible explanation for this inverse
relation can be the changed turnover of matrix components in OA
such as formation of new collagen. It has been demonstrated that
collagen AGE levels are greatly inﬂuenced by the rate of collagen
Table II
Results of multiple regression analysis with each of the OA parameters as dependent variable (column 1) and ln skin pentosidine/collagen and age as independent variables
entered backwards. The explained variance in each model is shown as R2. The partial regression coefﬁcient for age (B age) and ln cartilage pentosidine (B ln cart pent) is given.
For cartilagemicroscopy, PG synthesis, % total PG and % newly formed GAG released the total model shows a signiﬁcant explanation for the dependent variable, where cartilage
pentosidine is the only dependent variable as explanation. P values are indicated and considered statistically signiﬁcant when below 0.05
Outcome R square P B age 95% CI interval P B ln cart pent 95% CI interval P
Cartilage macroscopy 0.065 0.154 0.004 0.020 to þ0.013 0.671 0.232 0.560 to þ0.095 0.161
Cartilage histology 0.192 0.003 0.010 0.024 to þ0.043 0.566 1.103 1.757 to 0.449 0.001
PG synthesis 0.453 0.001 0.024 0.005 to þ0.053 0.102 0.604 0.028 to þ1.182 0.040
% total PG released 0.392 0.009 0.003 0.132 to þ0.127 0.969 3.525 6.114 to 0.937 0.008
% newly formed GAG released 0.444 0.002 0.017 0.238 to þ0.272 0.894 8.270 13.347 to 3.192 0.002
PG content 0.231 0.209 0.059 0.273 to þ0.154 0.581 3.175 0.544 to þ7.974 0.086
K&L score 0.020 0.538 0.010 0.010 to þ0.031 0.322 0.010 0.423 to þ0.402 0.960
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cartilage degeneration the collagen turnover is higher compared to
samples from knees without signs of degeneration28. Pentosidine
levels in newly formed cartilage tissue (granulated tissue) were
lower compared to older cartilage samples in the cartilage obtained
from the same joint at joint replacement15. Cartilage from OA
patients shows loss of background AGE ﬂuorescence centred on
chondrocytes, and more extensive ﬂuorescence near the surface29.
The pattern of ﬂuorescence loss is distinct from that of PG loss, but is
generally similar to the distribution of collagen type-II denaturation
products. This indicates that chondrocytes in OA cartilage mediate
destruction and turnover of AGE-modiﬁed-collagen, followed by
the deposition of new, non-AGE-modiﬁed-collagen29. Moreover,
consistent with the occurrence of increased aggrecan turnover
during the OA disease process, aggrecan isolated from OA cartilage
contains less pentosidine than aggrecan from normal cartilage30. So,
in case of more severe OA the cartilage can contain lower amount of
pentosidine due to the newly formed collagen not yet modiﬁed by
the non-enzymatic glycation.
Both OA and AGEs strongly depend on age. In multiple regres-
sion analysis we observed that cartilage pentosidine can explain
the outcome measures of OA, age not being a confounder (Table II).
Another method to look at the residence time of proteins in
tissue is to use the amount of racemization. In nature, amino acids
are synthesized as L-isomers. Racemization converts them slowly to
the D-form. Aspartic acid is one of the fastest racemizing amino
acids31. Racemization of aspartic acid can be used to gain infor-
mation on the residence time of aggrecan in cartilage, the %D-
aspartic acid (%D-asp) can be used as a measure of the residence
time of a protein. In the present studywe found amoderate positive
correlation between the %D-asp and pentosidine levels of the
cartilage (R ¼ 0.485, P < 0.001; data not shown). This indicates that
the cartilage with long-lived collagen (higher amount of %D-asp)
has a higher amount of pentosidine. For the cartilage histology
a negative correlation was found with %D-asp (R ¼ 0.425,
P ¼ 0.001; data not shown), further supporting that the stronger
cartilage damage is associated with increased tissue remodelling
and consequently newer proteins in the cartilage tissue. Taken
together these results can be an explanation for the inverse rela-
tionship with pentosidine and actual OA damage.
It is tempting to evaluate biochemical markers of cartilage
turnover to provide additional proof for the enhanced turnover as
mechanism of the inverse relationship between cartilage pentosi-
dine and OA damage. However, this enhanced turnover may (and
will have) occurred over the years of progression of the cartilage
damage. Biochemical markers of cartilage turnover would only
provide information of turnover at this moment. Racemization of
aspartic acid is the result of turnover over the years and as such
considered a good support for the proposed explanation.
In this study only pentosidine was measured as a representative
measurement of AGEs. Other measurements have been described,i.e., Nε-carboxymethyllysine (CML) and N 3-carboxyethyllysine
(CEL). These markers for AGEs were not measured. Because earlier
studies showed a close relationship between all these different
markers and age17, we assume that other measurements show
similar results. Nonetheless, the inclusion of other markers might
have strengthen our conclusion.
The negative correlation between the release of total and newly
formed PGs with higher amount of pentosidine [Fig. 3(B and C)] can
also be explained due to a changed turnover of PGs or less actual
loss from the cartilage matrix. Accumulation of AGEs results in
a decreased susceptibility to chondrocyte mediated degradation of
the cartilage matrix32. Release of PGs and collagen from the
extracellular matrix by both chondrocyte-derived proteinases and
synovial ﬂuid proteinases is decreased at increased AGE levels. The
exact mechanism by which AGE accumulation results in dimin-
ished PG release remains unclear. Accumulation of AGEs may
render proteins less susceptible to degradation by interfering with
proteinase-substance interactions: AGEs change protein charge and
conformation and/or may cause sterical hindrance and thereby
interfere with proteinase-substrate interactions. Glycation of
cartilage changes biophysical properties of the matrix proteins and
thereby possibly affects the permeability of the matrix for
proteinases33. In addition, increased inter- and intramolecular AGE
crosslinks may diminish the release of degraded cartilage constit-
uents34. Also, production of MMP’s by chondrocytes is decreased in
a glycated environment and results in a decreased collagen
degradation35. This means that with increased AGE levels less PGs
fragments are available for release.
The level of PG content in the cartilage tissue is not statistically
signiﬁcant associated with pentosidine levels. The reason is that PG
content is a less sensitive measurement than synthesis and release
and is the cumulative result of changes of synthesis and release
over time, whereas synthesis and release itself are momentary
(dynamic) parameters. This explains why PG content is not and
synthesis and release are related to pentosidine levels.
Urinary pentosidine is measured in a momentum dependent on
various factors including peripheral turnover. In these end-stage
OA patients we observed the same relations with cartilage turn-
over as for cartilage pentosidine. In case of early OA we could not
ﬁnd a relation with radiographic OA and urinary pentosidine11. The
difference between these observations is that the latter study uses
a surrogate marker for cartilage OA (radiographs) and is based on
early OA. In case of end-stage OA, as in the present study, the
turnover of the cartilage may be more outspoken compared to
early OA.
In conclusion, there is an inverse relation between AGEs and
actual cartilage damage measured on different levels in end-stage
OA using the cartilage tissue itself. This is contrasting the existing
literature which makes use of indirect measurements. Whether
AGEs play a role in the progression of OA remains unclear at this
moment.
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